To assess the clinical heterogeneity among patients with acute lymphoblastic leukemia (ALL) and various 11q23 abnormalities, we analyzed data on 497 infants, children and young adults treated between 1983 and 1995 by 11 cooperative groups and single institutions. The substantial sample size allowed separate analyses according to age younger or older than 12 months for the various cytogenetic subsets. Infants with t(4;11) ALL had an especially dismal prognosis when their disease was characterized by a poor early response to prednisone (P = 0.0005 for overall comparison; 5-year event-free survival (EFS), 0 vs 237 712% s.e. for those with good response), or age less than 3 months (P = 0.0003, 5-year EFS, 57 75% vs 23.47 74% for those over 3 months). A poor prednisone response also appeared to confer a worse outcome for older children with t(4;11) ALL. Hematopoietic stem cell transplantation failed to improve outcome in either age group. Among patients with t(11;19) ALL, those with a T-lineage immunophenotype, who were all over 1 year of age, had a better outcome than patients over 1 year of age with B-lineage ALL (overall comparison, P = 0.065; 5-year EFS, 887 713 vs 46714%). In the heterogeneous subgroup with del(11)(q23), National Cancer Institute-Rome risk criteria based on age and leukocyte count had prognostic significance (P = 0.04 for overall comparison; 5-year EFS, 647 78% (high risk) vs 837 76% (standard risk)). This study illustrates the marked clinical heterogeneity among and within subgroups of infants or older children with ALL and specific 11q23 abnormalities, and identifies patients at particularly high risk of failure who may benefit from innovative therapy.
Introduction
The frequency of 11q23/MLL gene rearrangements in infant (o1 year) acute lymphoblastic leukemia (ALL) is as high as 75% when studied with molecular techniques. 1 The t(4;11) (q21;q23) with MLL-AF4 fusion is by far the most prevalent subtype of 11q23/MLL rearrangement. Numerous studies in the 1980s linked both infant ALL and the t(4;11) with a poor prognosis. 2, 3 Initially, it was not certain whether the overall poor outcome of infant ALL was related to the preponderance of t(4;11) rearrangements in this age group. In 1991, a collaborative study of the Pediatric Oncology Group and St Jude Children's Research Hospital demonstrated considerable clinical heterogeneity among patients with the t(4;11); that is, children 1-9 years old fared significantly better than infants and older children, 4 a finding subsequently confirmed by others. 3, 5 This age-dependent prognostic significance was later extended to the t (11;19) and other 11q23 translocations. [6] [7] [8] In 1993, Chen et al 9 showed that any 11q23 molecular rearrangement was associated with a poor outcome in infant ALL cases, a finding confirmed by many other studies. [10] [11] [12] [13] [14] However, investigators of the Children's Cancer Group suggested that infants with the t(4;11) had a particularly poor outcome. 15, 16 To clarify the extent and therapeutic implications of the clinical heterogeneity associated with specific 11q23 rearrangements, we recently reviewed a large cohort of patients with 11q23 abnormalities that had been treated by 11 cooperative groups and single institutions. 17 In a multivariate analysis, age was found to be the most important prognostic factor: infants younger than 1 year fared significantly worse than patients 1 year of age or older. In the infant cases, any 11q23 abnormality conferred a dismal prognosis, whereas in older patients, t(4;11) and t(9;11) were associated with a worse outcome than were other 11q23 rearrangements. In the t(4;11) cases, allogeneic transplantation, even with HLA-matched related donors, failed to improve outcome. In the current study, we sought to identify additional prognostic factors that may be useful in selecting subsets of patients who would benefit most from alternative therapy. We also analyzed the efficacy of hematopoietic stem cell transplantation separately for infants and children over 1 year of age with t(4;11) ALL.
Patient and methods

Study population
Between 1983 and 1995, 497 patients with 11q23 chromosomal abnormalities, MLL rearrangements, or MLL-AF4 fusion transcripts were enrolled in the clinical trials of 11 cooperative study groups and single institutions in the USA and Europe. Follow-up observations extended through July 2000 (median, 7 years; range, 1.5-16.7 years). The overall clinical outcome of these patients was reported previously. 17 About 90% of the patients were treated according to protocols for higher-risk or very highrisk subtypes of ALL. Hematopoietic stem cell transplantation during initial remission was performed in 68 patients, 56 of whom had a t(4;11) translocation.
Statistical analysis
For analytical purposes, cases were first divided into five genetic subgroups: t(4;11), n ¼ 256; t(11;19), n ¼ 49; t(9;11), n ¼ 20; del(11)(q23), n ¼ 95; and other 11q23/MLL abnormalities, n ¼ 77. Since an age o12 months was the most important adverse prognostic factor in our previous study, 17 cases were further subdivided by age (o1 or X1 years). The principal end point was event-free survival (EFS), measured from the start of therapy to the date of first treatment failure of any kind (relapse, death or second malignancy) or to the last date of follow-up. Failure to enter remission was considered an event at zero time. Disease-free survival is EFS for patients who achieved a complete remission. Distributions of EFS were estimated by the method of Kaplan and Meier and compared with the exact log-rank test. Stratified Cox's proportional-hazards regression analyses were used to investigate the potential associations of age, gender, leukocyte count at diagnosis (o50 vs 450 Â 10 9 /l), central-nervous-system (CNS) leukemia, and National Cancer Institute-Rome risk criteria (standard vs high) 18 with EFS, with hematopoietic cell transplantation included as a time-dependent covariate. The hazard ratios and their associated P-values were from models based on the factor of interest stratified by the remaining factors, if appropriate. Prednisone response (blast cell count 4 or o1 Â 10 9 /l after 7 days of prednisone and one dose of intrathecal methotrexate) was assessed among patients with available data, with the use of a Cox proportionalhazards model that included transplantation as a time-dependent covariate, stratified for age and leukocyte count at diagnosis.
Cox's proportional-hazards regression models adjusted for the presenting leukocyte count and the waiting time to transplantation were used to assess, in separate analyses, the effects of various types of transplantation on the disease-free survival in infants or older patients with the t(4;11) translocation. Three patients were excluded from analysis because of unknown initial leukocyte count or age. The Stram-Sather test 19 was used to compare overall survival between patients who received chemotherapy only and those undergoing transplantation after initial chemotherapy.
Results
t(4;11) ALL
Among patients with the t(4;11) translocation, infants younger than 1 year had a worse outcome than did older patients (overall comparison, P ¼ 0.0001; 5-year EFS7s.e., 1973 vs 4275%; hazard ratio 1.8 [95% CI, 1.3-2.3], Po0.001). In the infant subgroup, a particularly poor outcome was observed among patients with a poor prednisone response, defined as the presence of X1000 blast cells/ml after 7 days of initial treatment with prednisone and one dose of intrathecal methotrexate (P ¼ 0.0005, 5-year EFS, 0 vs 23712%; hazard ratio 4.5 [95% CI, 1.2-17.1], P ¼ 0.025; Figure 1 ). Although there was no significant difference in outcome between infants 3-6, 6-9 and 9-12 months old (P ¼ 0.58), those o3 months old had a significantly inferior outcome, as compared to all infants aged 3-12 months old (P ¼ 0.0003 for overall comparison; 5-year EFS, 575% vs 23.474%; hazard ratio 1.9 [95% CI, 1.2-2.9], P ¼ 0.004; Table 1 ). Presenting leukocyte count failed to attain independent significance in a multivariate analysis after adjusting for age (o3 vs X3 months), CNS status and sex (hazard ratio, 1.4 [95% CI, 0.79-2.5,
In a Cox proportional-hazards model adjusted for initial leukocyte count and waiting time to transplantation, infants who received any type of transplant had a worse disease-free survival than did patients treated with chemotherapy alone (Table 2) . Even transplantation with stem cells from HLA-matched related donors failed to improve the clinical outcome. An analysis based on overall survival yielded similar results (data not shown).
In patients 1 year of age or older with t(4;11) ALL, the presenting leukocyte count lacked prognostic significance (P ¼ 0.93, Figure 2 ). Stem cell transplantation, even from HLAmatched donors, failed to improve disease-free survival (Table 3) or survival in general (data not shown), compared with patients receiving chemotherapy only. The sole factor with apparent prognostic impact in this older subgroup was poor response to prednisone (P ¼ 0.077; EFS7s.e., 33716 vs 80718%); the lack of significance in this comparison was probably because of small number of patients.
t(11;19) ALL
Age under 1 year conferred a worse outcome in patients with t(11;19) ALL: (5-year EFS7SE, 2678% vs 64712% in older patients; overall comparison, P ¼ 0.003; hazard ratio 2.9 [95% CI, 1.3-6.7], P ¼ 0.01). Among the infant subgroup, age less than 6 months and female sex were associated with an inferior treatment outcome (Table 4) . However, neither factor achieved independent significance in multivariate analysis (data not shown). T-lineage ALL was marginally associated with a more Figure 1 EFS in infants with t(4;11) ALL according to the blast cell count after 7 days of prednisone treatment and one dose of intrathecal methotrexate. Patients with good response had o1000 blast cells/ml, while those with a poor response had higher counts. P ¼ 0.0005 by log-rank analysis.
Childhood ALL with 11q23 rearrangements C-H Pui et al favorable outcome than B-lineage ALL in the X1-year subgroup ( Figure 3 , P ¼ 0.065).
t(9;11) ALL
Infant age was neither a significant predictor of outcome in patients with t(9;11) ALL (overall comparison, P ¼ 0.266; 5-year EFS7s.e., 38715% vs 46714%) nor were there any significant prognostic factors within the discrete infant age categories.
Infants with a leukocyte count o50 Â 10 9 /l at diagnosis appeared to have a better outcome than those with a higher count (Table 5 ), although the difference was not statistically significant (P ¼ 0.085 for the overall comparison).
del(11)(q23)
There were only five infants with the del(11)(q23) and their treatment outcome was inferior to that of the 89 older children 
Other 11q23/MLL abnormalities
Recurrent chromosomal rearrangements identified in 23 infants in this subgroup included inv(11)(p15q23) (n ¼ 5), t(1;11) (p32;q23) (n ¼ 5), t(10;11)(p14-15;q23) (n ¼ 4), t(1;11)(q23;q23) (n ¼ 2) and t(10;11)(p13;q23) (n ¼ 2). These 23 infants fared significantly worse than the 54 older patients (overall comparison, P ¼ 0.0001; 5-year EFS7s.e., 2278 vs 6577%); hazard ratio 3.4 [95% CI, 1.7-6.7], Po0.001). No other significant prognostic factors could be identified in this heterogeneous group of cases.
Discussion
This study demonstrates the clinical heterogeneity among patients with ALL defined by specific 11q23/MLL rearrangements, even within the infant and older subgroups. The results underscore recent observations that specific cytogenetic abnormalities do not necessarily define homogeneous treatment groups. 20, 21 A poor prednisone response identified a subset with a particularly poor outcome among our infants cases with the t(4;11), and also suggested a poorer outcome in the small cohort of older patients with the same genetic abnormality. However, data on prednisone response were available in only a small subset of our patients and hence additional studies are needed to confirm the finding. To this end, a Children's Cancer Group study of infant ALL found that a slow response to remission induction therapy, as judged from day-14 marrow findings, was an independent adverse prognostic factor after adjustment for t(4;11) and CD10 status. 22 In a Berlin-Frankfurt-Mü nster Study, a poor prednisone response was the strongest predictor of outcome in infant ALL and approached independent significance among t(4;11) cases, despite the limited number of cases studied (n ¼ 16). 23 These results are not surprising, as treatment response reflects not only the intrinsic drug resistance/sensitivity of leukemic cells, but also the pharmacokinetics, pharmacodynamics and pharmacogenetics of the host. 24 Further analysis of the predictive strength of responses to early prednisone treatment among other cytogenetically defined subgroups was precluded by their small numbers.
Presenting leukocyte count had only a marginal prognostic impact in infants with t(4;11) ALL and lacked significance EFS for children 1 year of age or older with the t(4;11) ALL according to leukocyte count at diagnosis (P ¼ 0.989 by log-rank analysis). Table 3 Types of failures and estimated hazard ratio for disease-free survival according to transplant vs chemotherapy alone in patients 1 year or older with t(4;11) ALL Childhood ALL with 11q23 rearrangements C-H Pui et al altogether in older children with this genetic subtype of the disease (Figure 2 ). The failure of higher leukocyte count increments to adversely affect outcome has also been noted in T-cell ALL, [25] [26] [27] [28] another leukemia usually presenting with a high leukemic cell burden.
Previous studies have shown that in t(11;19) ALL, T-lineage cases have a more favorable outcome than B-lineage cases. 6, 7, 29 Among the total of 18 T-cell cases reported in these three studies, 17 were above 1 year of age at diagnosis and all but one remained in first complete remission at the time of being reported. Similarly, in our study, all eight T-cell cases with t (11;19) were over 1 year of age at diagnosis and only one of them had an adverse event.
In ALL, deletions of the 11q23 region [del(11)(q23)] generally do not involve MLL gene and represent a heterogeneous group of patients. [30] [31] [32] Indeed, the presenting features of our cohort with this abnormality did not differ substantially from those of the general ALL population. Not surprisingly, risk assessment according to the National Cancer Institute-Rome criteria 18 had prognostic significance. There were too few patients with other 11q23 abnormalities to allow meaningful risk factor analyses.
In our previous analysis, we found that any type of hematopoietic stem cell transplant was associated with a significantly worse outcome than chemotherapy alone in patients with the t(4;11), after adjustment for age, leukocyte count at diagnosis and time to transplantation. 17 Here, in separate analyses according to age at presentation, we again show that transplantation even from an HLA-matched related donor does not improve outcome. This result agrees with findings of the United Kingdom Medical Research Council, who found no significant difference in EFS among patients with 11q23 abnormalities treated with either chemotherapy or EFS for patients with the t(11;19) ALL according to leukemic cell lineage and age at diagnosis. No infants had T-cell ALL with this rearrangement. P ¼ 0.065 by log-rank analysis.
Childhood ALL with 11q23 rearrangements C-H Pui et al transplantation on the Infant 92 protocol. 33 However, it should be noted that patients in this study were treated between 1983 and 1995, and the number of patients in each subgroup is small, limiting the power of statistical analyses. In view of the continuous improvement in chemotherapy as well as transplantation, 24 ,34 similar studies should be conducted in patients treated with modern therapy.
Although occasional subgroups with 11q23 rearrangements had a favorable prognosis, the vast majority of patients with these genetic alterations fared poorly on standard treatments for high-risk disease. Limited results of clinical and in vitro drug sensitivity testing suggest that leukemic cells from t(4;11) ALL or infant ALL, in general, are more sensitive to cytarabine than are cells from the other patients with ALL. [35] [36] [37] Two large ongoing international infant ALL studies (Children's Oncology Group and Interfant) are evaluating the efficacy of intensified therapy that includes high-dose cytarabine. Although the preliminary results of one study appear promising, with a 2-year EFS of 60% in infants with MLL rearrangements, 38 it remains to be determined if these intensified regimens will improve the dismal outlook of infants with a poor early response to therapy. The failure of hematopoietic stem cell transplantation to improve clinical outcome in the subgroups analyzed here suggests that greater emphasis should be placed on the eradication of residual drug-resistant leukemic cells, the source of most treatment failures in this series. Among the new antileukemic agents now under development, FLT-3-targeted tyrosine kinase inhibitors may be useful in therapy for MLL-rearranged ALL, as recent studies have disclosed high levels of FLT-3 expression in such cases, and the kinase inhibitors have produced cytotoxic responses in vitro. Childhood ALL with 11q23 rearrangements C-H Pui et al
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